No Data
No Data
Chongqing Zhifei Biological Products (300122.SZ): Currently, there are 13 products listed and available for sale.
Chongqing Zhifei Biological Products (300122.SZ) stated on the investor interaction platform that the company currently has 13 products on the market, 1 product conditionally approved, including vaccines for infectious diseases such as meningococcal, cervical cancer, pneumonia, rotavirus, and herpes zoster, as well as drugs that provide effective solutions for the diagnosis, prevention, and treatment of tuberculosis infection, covering populations including infants, adolescents, and adults. At the same time, one product is in the stage of applying for marketing approval, two products have completed clinical trials, and six products are in phase III clinical trials. The company's extensive marketing network can enable
Is It Smart To Buy Chongqing Zhifei Biological Products Co., Ltd. (SZSE:300122) Before It Goes Ex-Dividend?
Chongqing Zhifei Biological Products (300122.SZ) plans to distribute 8 yuan per 10 shares in 2023, with the ex-right and ex-dividend date on August 8th.
Chongqing Zhifei Biological Products (300122.SZ) announced that it plans to distribute cash to all shareholders in the year 2023, with a distribution ratio of 10 shares per shareholder...
Chongqing Zhifei Biological Products (300122.SZ): Quadrivalent recombinant norovirus vaccine enters Phase III clinical trial.
Chongqing Zhifei Biological Products (300122.SZ) announced on July 29 that the company has recently learned that the quadrivalent recombinant norovirus vaccine (Bacillus yeast) (hereinafter referred to as the "quadrivalent recombinant norovirus vaccine") developed by its wholly-owned subsidiary Anhui Zhifei Longma Biopharmaceutical Co., Ltd. has entered Phase III clinical trials in Guangxi, Hunan, and Sichuan. The quadrivalent recombinant norovirus vaccine contains the currently main prevalent strains and genotypes of norovirus and is prepared using gene engineering technology to express virus-like particles (VLPs). Norovirus is the main pathogen causing outbreaks of acute gastroenteritis in the world, affecting approximately one-fifth of the global population.
Chongqing Zhifei Biological Products (300122.SZ): As of July 19th, the number of ordinary shareholders of the company is 0.1111 million.
Chongqing Zhifei Biological Products (300122.SZ) stated on the investor interaction platform on July 26th that as of July 19th, 2024, the number of common shareholders of the company was 111,092.
Chongqing Zhifei Biological Products (300122.SZ) has seven self-developed products on the market, one of which is conditionally listed, including vaccine products for preventing meningitis, pneumonia, and other infectious diseases.
Chongqing Zhifei Biological Products (300122.SZ) stated on the investor interaction platform that the company has 7 proprietary products on the market and 1 proprietary product conditionally approved for listing, including vaccines for preventing infectious diseases such as meningitis and pneumonia, as well as drugs that provide effective solutions for the diagnosis, prevention, and treatment of tuberculosis infections. The company has a total of 31 research projects, among which the quadrivalent flu vaccine is in the stage of applying for listing, and clinical trials of freeze-dried human rabies vaccine (MRC-5 cells) and influenza virus split vaccine have been completed. Five products including the 15-valent pneumococcal conjugate vaccine and fractional pertussis vaccine are in phase III clinical trials.
No Data